Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)

被引:63
|
作者
Humenberger, Magdalena [1 ,2 ]
Horner, Andreas [1 ,2 ]
Labek, Anna [3 ]
Kaiser, Bernhard [3 ]
Frechinger, Rupert [4 ]
Brock, Constanze [1 ]
Lichtenberger, Petra [1 ]
Lamprecht, Bernd [1 ,2 ]
机构
[1] Kepler Univ Hosp, Dept Pulmonol, Krankenhausstr 9, A-4021 Linz, Austria
[2] Johannes Kepler Univ Linz, Fac Med, Linz, Austria
[3] Upper Austrian Hlth Insurance, Dept Hlth Econ, Linz, Austria
[4] Kepler Univ Hosp, Dept Med Controlling, Linz, Austria
来源
BMC PULMONARY MEDICINE | 2018年 / 18卷
关键词
Chronic obstructive pulmonary disease; Adherence; Inhaled therapy; PATIENT ADHERENCE; RISK-FACTORS; MEDICATIONS; ASTHMA; EXACERBATIONS; NONADHERENCE; PERSISTENCE; PREVALENCE; OUTCOMES; BURDEN;
D O I
10.1186/s12890-018-0724-3
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundCOPD is a treatable disease with increasing prevalence worldwide. Treatment aims to stop disease progression, to improve quality of life, and to reduce exacerbations. We aimed to evaluate the association of the stage of COPD on adherence to inhaled therapy and the relationship between adherence and COPD exacerbations.MethodsA retrospective analysis of patients hospitalized for acute exacerbation of COPD in a tertiary care hospital in Upper Austria and discharged with a guideline conform inhaled therapy was performed. Follow-up data on medical utilization was recorded for the subsequent 24months. Adherence to inhaled therapy was defined according to the percentage of prescribed inhalers dispensed to the patient and classified as complete (>80%), partial (50-80%) or low (<50%).ResultsOut of 357 patients, 65.8% were male with a mean age of 66.5years and a mean FEV1 of 55.0%pred. Overall, 35.3% were current smokers, and only 3.9% were never-smokers. In 77.0% inhaled triple therapy (LAMA + LABA + ICS) was prescribed. 33.6% showed complete adherence to their therapy (33.2% in men, 34.4% in women), with a mean age of 67.0years. Mean medication possession ratio by GOLD spirometry class I - IV were 0.486, 0.534, 0.609 and 0.755, respectively (p=0.002). Hence, subjects with complete adherence to therapy had a significantly lower FEV1 compared to those with low adherence (49.2%pred. vs 59.2%pred., respectively; p<0.001).The risk of exacerbations leading to hospitalization was 10-fold higher in GOLD spirometry class IV compared to GOLD spirometry class I, which was even more evident in multivariate analysis (OR 13.62).ConclusionComplete adherence to inhaled therapy was only seen in 33.6% and was higher among those with more severe COPD.Trial registrationNot applicable.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Chronic Obstructive Pulmonary Disease (COPD)
    Gillissen, Adrian
    Rasche, Kurt
    MEDIZINISCHE KLINIK, 2006, 101 (07) : 559 - 570
  • [42] Chronic obstructive pulmonary disease (COPD)
    Pahl, Andreas
    Szelenyi, Istvan
    DRUGS OF THE FUTURE, 2007, 32 (09) : 799 - 807
  • [43] Chronic Obstructive Pulmonary Disease (COPD)
    Weitzenblum, E.
    EUROPEAN RESPIRATORY REVIEW, 2009, 18 (112): : 133 - 133
  • [44] Chronic obstructive pulmonary disease (COPD)
    Senior, RM
    Anthonisen, NR
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (04) : S139 - S147
  • [45] Chronic Obstructive Pulmonary Disease (COPD)
    S. Desole
    C. M. Kähler
    memo - Magazine of European Medical Oncology, 2008, 1 (Suppl 3) : 3 - 6
  • [46] Chronic obstructive pulmonary disease (COPD)
    Pommer, Peter
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (49) : 2589 - 2589
  • [47] Chronic obstructive Pulmonary Disease (COPD)
    Koczulla, A. -R.
    Greulich, T.
    Beutel, B.
    Vogelmeier, C.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (22) : 1185 - 1187
  • [48] ADHERENCE TO SINGLE AND MULTIPLE INHALED TRIPLE THERAPIES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY, CONSIDERING DIFFERENT DEFINITIONS
    Requena, G.
    Rothnie, K.
    Noorduyn, S. G.
    Claussen, J.
    Schultze, M.
    Kossack, N.
    Richter, L.
    Vogelmeier, C.
    Beeh, K. M.
    Sharma, R.
    Compton, C.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S499 - S499
  • [49] Inhaled Corticosteroid (ICS) Use in Chronic Obstructive Pulmonary Disease (COPD) and the Risk of Pneumoniaa
    Kahler, Kristijan H.
    Yawn, Barbara
    Tian, Haijun
    Li, Frank
    Zhang, Jie
    Arcona, Steve
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 20 - 20
  • [50] Inhaled SalmeterolA Review of its Efficacy in Chronic Obstructive Pulmonary Disease
    Blair Jarvis
    Anthony Markham
    Drugs & Aging, 2001, 18 : 441 - 472